DRUG
Mazdutide
Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period.
Status
Recruiting
Phase
Not applicable
Enrollment
420
Locations
13
Results
Not posted
Publications
0
Study summary
Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.
Interventions
DRUG
Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period.
BEHAVIORAL
A structured intensive lifestyle intervention including individualized dietary counseling, physical activity guidance, and behavioral modification support for 52 weeks during the weight maintenance period.
Timeline
First posted
Apr 8, 2026
Study start
Apr 2026
Primary completion
Dec 2028
Study completion
Dec 2028
Results posted
Not reported
Registry updated
Apr 8, 2026
Outcomes
Percentage change of body weight
Time frame · From randomization to Week 52
Change in body mass index (BMI)
Time frame · From randomization to Week 52
Change in waist circumference
Time frame · From randomization to Week 52
Change in total body fat
Time frame · From randomization to Week 52
Change in abdominal visceral fat area
Time frame · From randomization to Week 52
Abdominal visceral fat area is quantified by CT scan
Change in hepatic fat content
Time frame · From randomization to Week 52
Hepatic fat content is quantified by controlled attenuation parameter (CAP), measured by Fibroscan.
Change in blood pressure
Time frame · From randomization to Week 52
Change in serum lipid profile
Time frame · From randomization to Week 52
Changes in blood glucose
Time frame · From randomization to Week 52
Changes in insulin sensitivity
Time frame · From randomization to Week 52
Insulin sensitivity is assessed by HOMA-IR index
Changes in pancreatic β-cell function
Time frame · From randomization to Week 52
Pancreatic β-cell function is assessed by HOMA-β index
Eligibility
Inclusion Criteria: * Adult men or women aged 18 years or older; * Simple obesity, defined as a body mass index (BMI) of 28.0-45.0 kg/m²; * Able and willing to provide written informed consent. Exclusion Criteria: * Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other serious infectious or systemic diseases; * Severe hepatic impairment (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] \>3 times the upper limit of normal), severe renal impairment, or end-stage renal disease (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m²); * Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months; * Severe gastrointestinal diseases, or a history of gastrointestinal resection surgery within the past year; * Acute or chronic pancreatitis, gallbladder disease, or pancreatic injury; * Obesity secondary to other causes, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, or acromegaly; drug-induced obesity, such as obesity related to the use of antipsychotic agents or glucocorticoids; * Current smoker or habitual smoking within the past 3 months; * Current use of other weight-loss medications or a history of bariatric surgery; * Previously diagnosed diabetes mellitus or current use of glucose-lowering medications; * Pregnant or breastfeeding women, or women planning pregnancy during the study period; * Inability to complete a 2-year follow-up due to health conditions, relocation, or other reasons; * Any other condition deemed by the investigator to make the participant unsuitable for participation in the study.
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fujian Provincial Hospital, Affiliated to Fuzhou University
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China
The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University
Suzhou, Jiangsu, China
Huadong Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Tenth People's Hospital, School of Medicine, Tongji University
Shanghai, Shanghai Municipality, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
West China Hospital · Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis
Phase 2 / Phase 3
Not yet recruiting
60
2026-07
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Tianjin Medical University · Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
Not applicable
Not yet recruiting
72
2026-07
Eli Lilly · Alcohol Use Disorder
Phase 2
Completed
308
2026-07
China National Center for Cardiovascular Diseases · Obesity & Overweight · Coronary Heart Disease
Phase 4
Not yet recruiting
116
2026-06
Shandong Provincial Hospital · Prediabetes · Impaired Fasting Glucose
Phase 4
Not yet recruiting
150
2026-06
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes · Obesity
Phase 3
Completed
349
2026-06
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
200
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.